Trial · NCT07883902
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
NCT07883902, Not applicable, Not yet recruiting, Santiago Lopez Gil
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection. Trials, record NCT07883902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
- NCT number
- NCT07883902
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 406 participants, estimated
- Lead sponsor
- Santiago Lopez Gil
- Conditions
- Acute Respiratory Infection
- Interventions
- Expanded Diagnostic Strategy, Conventional Diagnostic Strategy
- First posted
- 2026-10-20
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total Duration of Antibiotic Therapy | From hospital admission through 30 days after hospital discharge | Total antibiotic exposure, calculated as the sum of days of therapy for all antibiotics received for the index acute respiratory infection, including antibiotic therapy administered during hospitalization and antibiotic therapy prescribed at hospital discharge. Each antibiotic received on a given calendar day contributes one day of therapy; therefore, days of concomitant antibiotic therapy are counted separately for each antibiotic. |
| Secondary | Duration of High Impact Antibiotic Therapy | From hospital admission through 30 days after hospital discharge | Total exposure to high-impact antibiotics, calculated as the sum of days of therapy for all high-impact antibiotics received for the index acute respiratory infection. High-impact antibiotics are predefined as levofloxacin, moxifloxacin, piperacillin-tazobactam, ceftaroline, ceftobiprole, cefiderocol, cefepime, ceftazidime-avibactam, ceftolozane-tazobactam, carbapenems, vancomycin, and linezolid. Each antibiotic received on a given calendar day contributes one day of therapy; concomitant antibiotics are counted separately. |
| Secondary | Antibiotic De-escalation | From hospital admission through 30 days after hospital discharge | Proportion of participants in whom antibiotic therapy is de-escalated during the index hospitalization or after discharge. Antibiotic de-escalation is defined as switching from a high-impact antibiotic to a low-impact antibiotic or discontinuing antibiotic therapy, according to the predefined classification in the study protocol. |
| Secondary | Antibiotic Escalation | From hospital admission through 30 days after hospital discharge | Proportion of participants requiring escalation to high-impact antibiotic therapy for the index acute respiratory infection. Antibiotic escalation is defined as the need to change to an antibiotic classified as high-impact according to the predefined classification in the study protocol. |
| Secondary | Pathogen Detection by Pneumonia Panel PCR | Within the first 24 hours after hospital admission | Proportion of participants in whom at least one pathogen is detected by the multiplex pneumonia panel PCR performed on a respiratory sample. |
| Secondary | Time to Microbiological Diagnosis | From hospital admission to hospital discharge (assessed at 30 days after discharge) | Time in hours from hospital admission to the availability of the microbiological result establishing the microbiological diagnosis. |
| Secondary | Detection of Multidrug-Resistant Microorganisms | From hospital admission through 30 days after hospital discharge | Proportion of participants in whom at least one multidrug-resistant microorganism is detected in any microbiological sample. Multidrug-resistant microorganisms are defined as methicillin-resistant Staphylococcus aureus (MRSA); Enterobacterales producing extended-spectrum beta-lactamases (ESBL), AmpC beta-lactamases, or carbapenemases; Pseudomonas aeruginosa resistant to at least one antibiotic in each of the following classes: penicillins, cephalosporins, carbapenems, fluoroquinolones, and aminoglycosides; carbapenem-resistant Acinetobacter baumannii; and Stenotrophomonas maltophilia. |
| Secondary | Respiratory Infection-Related Complications | From hospital admission through 30 days after hospital discharge | Proportion of participants who develop at least one complication related to the index acute respiratory infection, including empyema, sepsis, lung abscess, acute respiratory distress syndrome, multiorgan failure, or venous thromboembolism. |
| Secondary | Hospital Length of Stay | From hospital admission to hospital discharge (assessed at 30 days after discharge) | Total number of days from hospital admission to hospital discharge. |
| Secondary | Intensive Care Unit Admission | From hospital admission to hospital discharge (assessed at 30 days after discharge) | Proportion of participants requiring admission to the intensive care unit (ICU) during the index hospitalization. |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883902
GET https://conductscience.org/api/trials/v1/NCT07883902/registered?page=2